Forms of 5-azacytidine
AssigneesPharmion LLC, Ash Stevens, Inc.
InventorsDumitru Ionescu, Peter Blumbergs, Gary L. Silvey
Life of this patent
Estimating the term…
Abstract
The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising said forms.
Claims8
Form IV of 5-azacytidine characterized by a X-Ray Powder Diffraction pattern obtained by irradiation with Cu Kα X-rays which shows main peaks with interplanar spacings at:
- d(Å)
- 15.408
- 7.642
- 7.040
- 6.289
- 5.555
- 5.213
- 4.906
- 4.355
- 4.281
- 4.132
- 4.073
- 3.957
- 3.913
- 3.760
- 3.695
- 3.526
- 3.511
- 3.312
- 3.185
- 3.126
- 3.106
- 2.964
- 2.912
- 2.877
- 2.557
- 2.354
- 2.342.
Form V of 5-azacytidine characterized by a X-Ray Powder Diffraction pattern obtained by irradiation with Cu Kα X-rays which shows main peaks with interplanar spacings at:
- d(Å)
- 8.024
- 7.160
- 6.714
- 6.436
- 6.084
- 5.697
- 5.350
- 4.930
- 4.780
- 4.618
- 4.476
- 4.365
- 4.126
- 4.042
- 3.948
- 3.834
- 3.702
- 3.620
- 3.273
- 3.133
- 3.072
- 3.033
- 2.889
- 2.870
- 2.370.
Form VII of 5-azacytidine characterized by a X-Ray Powder Diffraction pattern obtained by irradiation with Cu Kα X-rays which includes diffraction peaks at 5.8, 11.5, 12.8, 22.4 and 26.6° 2θ.
Form VIII of 5-azacytidine characterized by a X-Ray Powder Diffraction pattern obtained by irradiation with Cu Kα X-rays which shows main peaks with interplanar spacings at:
- d(Å)
- 13.384
- 8.292
- 7.020
- 6.623
- 5.587
- 5.129
- 4.383
- 4.257
- 4.079
- 3.923
- 3.483
- 3.458
- 3.046
- 2.782
- 2.556
- 2.348.
Dependencies are inferred from the claim text.